Homepage

CNS Pharmaceuticals, Inc.

CNSP NASDAQ Categories PDF
Healthcare · Biotechnology · United States · Updated May 11, 1:58pm
$6.58
Price
$3.8M
Market Cap
4
Employees
0.54
Beta
Rami Levin
CEO
Business Description

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Business History
Price Overview
Last updated: May 11, 2026 1:58pm (just now)
$6.58
-0.71 (-9.74%)
Day Range
$5.80 – $7.60
52-Week Range
$1.90 – $34.80
50-Day MA
$3.01
200-Day MA
$5.86
Volume
178,594.32
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
API Direct from provider CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALC
Stock Price / EPS (Diluted)
-0.18
Stock Price: $6.58
EPS (Diluted): -35.75
P/B Ratio (Price vs net asset value)
API
Stock Price / Book Value Per Share
0.51
Stock Price: $6.58
Total Equity: $4.52M
Shares: 443,369
EV/EBITDA (Total value vs operating profit)
API
Enterprise Value / EBITDA
0.20
Market Cap: $3.78M
Total Debt: $328,571
Cash: $7.20M
EBITDA: -$15.83M
Enterprise Value (Takeover price (cap + debt - cash))
API
Market Cap + Total Debt - Cash
-$3.1M
Market Cap: $3.78M
Total Debt: $328,571
Cash: $7.20M
Gross Margin (Revenue left after direct costs)
API
Gross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
API
Operating Income / Revenue
0.0%
Operating Income: -$15.99M
Revenue: $0.00
Net Margin (Revenue left as actual profit)
API
Net Income / Revenue
0.0%
Net Income: -$15.85M
Revenue: $0.00
ROE (Profit from shareholder equity)
API
Net Income / Total Equity
-164.6%
Net Income: -$15.85M
Total Equity: $4.52M
ROIC (Profit from all invested capital)
API
NOPAT / Invested Capital
-329.5%
Operating Income: -$15.99M
Tax Rate: 0.0%
Equity: $4.52M
Total Debt: $328,571
Cash: $7.20M
Current Ratio (Can it pay short-term bills)
API
Current Assets / Current Liabilities
1.98
Current Assets: $8.10M
Current Liabilities: $4.10M
Debt/Equity (Leverage — debt vs equity)
CALC
Total Debt / Total Equity
0.07
Short-Term Debt: $328,571
Long-Term Debt: $0.00
Total Debt: $328,571
Total Equity: $4.52M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 443,369
Book Value/Share (Net assets per share)
CALC
(Total Assets - Total Liabilities) / Shares
$10.20
Total Equity: $4.52M
Shares: 443,369
FCF/Share (Real cash generated per share)
CALC
(Operating Cash Flow + CapEx) / Shares
$-31.19
Operating CF: -$13.81M
CapEx: -$18,175
Shares: 443,369
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
API
Last Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $6.58
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$15.85M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares CNSP against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Metric 2021 2022 2023 2024 2025
Revenue $0 $0 $0 $0 $0
Cost of Revenue $13,070 $11,756 $4,134 $3,306 $0
Gross Profit $-13,070 $-11,756 $-4,134 $-3,306 $0
Operating Expenses $14.5M $14.9M $18.9M $14.9M $16.0M
Operating Income -$14.5M -$14.9M -$18.9M -$14.9M -$16.0M
Net Income -$14.5M -$15.3M -$18.9M -$14.9M -$15.9M
EBITDA -$14.5M -$15.3M -$18.9M -$14.8M -$15.8M
EPS $-495,027.00 $-336,499.00 $-150,114.00 $-466.44 $-35.75
EPS (Diluted) — — — — —
Balance Sheet (Annual)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $5.0M $10.1M $548,721 $6.5M $7.2M
Total Current Assets $7.5M $12.6M $1.6M $8.7M $8.1M
Total Assets $8.8M $13.1M $1.7M $8.7M $8.6M
Current Liabilities $2.1M $4.9M $6.1M $2.5M $4.1M
Long-Term Debt $0 $0 $0 $0 $0
Total Liabilities $2.1M $4.9M $6.1M $2.5M $4.1M
Total Equity $6.6M $8.1M -$4.4M $6.2M $4.5M
Retained Earnings -$35.0M -$50.7M -$69.6M -$84.4M -$100.3M
Cash Flow (Annual)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow -$13.5M -$10.6M -$14.1M -$17.1M -$13.8M
Capital Expenditure $-5,748 $-4,422 $-3,901 $-4,188 $-18,175
Free Cash Flow -$13.5M -$10.6M -$14.1M -$17.1M -$13.8M
Acquisitions (net) $0 $0 $0 $0 $0
Debt Repayment — — — — —
Dividends Paid — — — — —
Stock Buybacks $0 $0 $0 $0 $-2,043
Net Change in Cash -$9.0M $5.1M -$9.5M $5.9M $739,636
Growth Trends (YoY %)
Metric 2022 2023 2024 2025
Revenue Growth — — — —
Gross Profit Growth +10.1% +64.8% +20.0% +100.0%
Operating Income Growth -3.1% -26.3% +21.0% -7.3%
Net Income Growth -5.4% -23.4% +21.2% -6.7%
EBITDA Growth -5.4% -23.6% +21.3% -6.7%
Community AI Feedback
Sign in to Contribute
No community reviews yet for CNSP. Be the first — export the analysis to your AI and contribute back.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27